Chemogel kills kidney cancer


HACKENSACK, NJ (Ivanhoe Newswire) — Urothelial cancer is cancer that begins in the lining of the urinary tract, bladder, and kidneys. Patients usually need surgery to remove tumors, followed by chemotherapy. In patients with kidney cancer, the organ may need to be removed if the cancer comes back. Now there’s a new treatment that could save patients’ kidneys.

Ralph Auriemma is a man used to being on the move, having been on the road all his life as a tractor-trailer driver and construction worker. Two years ago, a red flag at his annual checkup.

“I used to have a trace of blood in my urine at every test, but this time it was more than a trace,” explains Auriemma.

Tests showed a kidney stone. A biopsy gave doctors more information.

“She says, ‘I have to tell you two things. one is good One is bad.’ She says: “You have cancer, but it’s a non-aggressive form. And we think we could treat it,” Auriemma says of his diagnosis.

“The tumor was about two centimeters in size. So about the size of a quarter,” said Dr. Ravi Munver of Hackensack University Medical Center.

dr Munver removed the cancer that was in the lining of the kidneys. But it kept coming, five times. At this point, Dr. Munver proposed an FDA-approved treatment called JELMYTO, which combines a chemotherapy drug called mitomycin and a chilled liquid that’s inserted into the body through a catheter. As the liquid warms to body temperature, it hardens into a gel.

dr Munver explains, “Because it’s a gel, it stays in the kidney for an hour or two. It will pass naturally through the system within a few hours.”

Auriemma was treated once a week for six weeks. Four months later there was no sign of tumor regrowth.

“I’m fine. One hundred percent. One hundred percent. I’m doing what I want again,” Auriemma told Ivanhoe News.

Chemogel: Kills cancer and helps surgeons save Auriemma’s kidney.

The FDA has approved JELMYTO for use in 2020, but some insurance companies have only recently started covering it. according to dr Munver, JELMYTO is intended for use in patients with early-stage, non-aggressive cancer. A clinical study found that in 84 percent of patients, the cancer did not return after treatment.

Copyright 2022 WILX. All rights reserved.

Subscribe to our News 10 newsletter and receive the latest local news and weather directly to your email every morning.


About Author

Comments are closed.